proline and arginine rich end leucine rich repeat proteinGenealiases: MST161 · MSTP161 · SLRR2A
Q-omics provides the consensus-scored PRELP profile across patient tissues and cancer cell-line models. PRELP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRELP is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PRELP protein abundance shows 28,950 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, BLCA, and PDAC as cancer lineages where PRELP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELP survival associations across molecular data types. PRELP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELP RNA expression–survival associations across cancer types. High PRELP expression shows unfavorable associations in KIRP, BLCA and COAD, but favorable associations in HNSC, LUAD and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRELP RNA expression.
This table summarizes PRELP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRELP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELP shows lower tumor expression in BLCA, KICH, KIRC, COAD, THCA and LUAD. The BLCA box plot shows higher PRELP RNA expression in normal versus tumor tissue (log2 FC = −5.268, t-test p < 0.001).
This table shows molecular features associated with PRELP in patient tissues and cancer cell lines. In patient samples, PRELP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRELP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
